Journal of Clinical Oncology· 2019Q1· Clinical trial

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle, Masatoshi Kudo et al.

1,824citations
Q1SCImago
2019year

Short summary

In advanced liver cancer patients previously treated with sorafenib, pembrolizumab plus best supportive care (BSC) showed a trend towards improved overall survival (OS) and progression-free survival (PFS) compared to placebo plus BSC, but did not meet statistical significance thresholds.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Hepatology

HepatologyMedicine